Physiological and molecular characterization of aristolochic acid transport by the kidney

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 2, 2011, Pages 588-597

  Dickman, Kathleen G ^a   Sweet, Douglas H ^b   Bonala, Radha ^a   Ray, Tapan ^c   Wu, Amy ^c  

^a STONY BROOK UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; CARBOXYL GROUP; FUNCTIONAL GROUP; METHOXY GROUP; NITRO GROUP; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PROBENECID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANION TRANSPORT; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VIVO STUDY; MALE; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; URINARY EXCRETION;

ANIMALS; ARISTOLOCHIC ACIDS; BIOLOGICAL TRANSPORT, ACTIVE; CHO CELLS; CRICETINAE; CRICETULUS; KIDNEY; MALE; MICE; MICE, INBRED C3H; ORGAN CULTURE TECHNIQUES; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS; RATS;

EID: 79960527351     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.180984     Document Type: Article

References (43)

1. Babu E, Takeda M, Nishida R, Noshiro-Kofuji R, Yoshida M, Ueda S, Fukutomi T, Anzai N, and Endou H (2010) Interactions of human organic anion transporters with aristolochic acids. J Pharmacol Sci 113:192-196.
2. Bakhiya N, Arlt VM, Bahn A, Burckhardt G, Phillips DH, and Glatt H (2009) Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology 264:74-79.
3. Berndt WO (1976) Use of the tissue slice technique for evaluation of renal transport processes. Environ Health Perspect 15:73-88.
4. Chan SA, Chen MJ, Liu TY, Fuh MR, Deng JF, Wu ML, and Hsieh SJ (2003) Determination of aristolochic acids in medicinal plant and herbal product by liquid chromatography-electrospray-ion trap mass spectrometry. Talanta 60:679-685.
5. Chan W, Cui L, Xu G, and Cai Z (2006) Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 20:1755-1760. (Pubitemid 43793879)
6. Cosyns JP (2003) Aristolochic acid and Chinese herbs nephropathy: a review of the evidence to date. Drug Saf 26:33-48.
7. Cosyns JP, Dehoux JP, Guiot Y, Goebbels RM, Robert A, Bernard AM, and van Ypersele de Strihou C (2001) Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int 59:2164-2173.
8. Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, and van Ypersele de Strihou C (1994a) Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 45:1680-1688.
9. Cosyns JP, Jadoul M, Squifflet JP, Van Cangh PJ, and van Ypersele de Strihou C (1994b) Urothelial malignancy in nephropathy due to Chinese herbs. Lancet 344: 188. (Pubitemid 24218887)
10. Debelle FD, Vanherweghem JL, and Nortier JL (2008) Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74:158-169. (Pubitemid 351915079)
11. 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos 34:1122-1127.
12. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, Yamamoto T, Sekine T, Cha SH, Niwa T, et al. (2002) Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 301:797-802. (Pubitemid 34595067)
13. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104:12129-12134. (Pubitemid 47185641)
14. Jackson L, Kofman S, Weiss A, and Brodovsky H (1964) Aristolochic acid (Nsc-50413): phase I clinical study. Cancer Chemother Rep 42:35-37.
15. Krumbiegel G, Hallensleben J, Mennicke WH, Rittmann N, and Roth HJ (1987) Studies on the metabolism of aristolochic acids I and II. Xenobiotica 17:981-991. (Pubitemid 17150543)
16. Lebeau C, Debelle FD, Arlt VM, Pozdzik A, De Prez EG, Phillips DH, Deschodt-Lanckman MM, Vanherweghem JL, and Nortier JL (2005) Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant 20:2321-2332. (Pubitemid 41548855)
17. Ljubojević M, Balen D, Breljak D, Kusan M, Anzai N, Bahn A, Burckhardt G, and Sabolić I (2007) Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones. Am J Physiol Renal Physiol 292:F361-F372.
18. McAuley B, Hickey MJ, Kingston LP, Jones JR, Lockley WJS, Mather AN, Spink E, Thompson SP, and Wilkinson DJ (2003) Convenient and efficient deuteration of functionalized aromatics with deuterium oxide: catalysis by cycloocta-1,5-dienyliridium(I)1,3-dionates. J Labelled Compounds Radiopharm46:1191-1204. (Pubitemid 37490196)
19. Mengs U (1987) Acute toxicity of aristolochic acid in rodents. Arch Toxicol 59:328-331.
20. Mengs U (1988) Tumour induction in mice following exposure to aristolochic acid. Arch Toxicol 61:504-505.
21. Mengs U, Lang W, and Poch J-A (1982) The carcinogenic action of aristolochic acid in rats. Arch Toxicol 51:107-119. (Pubitemid 13202139)
22. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, et al. (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342:1686-1692. (Pubitemid 30354515)
23. Pfau W, Schmeiser HH, and Wiessler M (1990a) Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 11:313-319. (Pubitemid 20072170)
24. Pfau W, Schmeiser HH, and Wiessler M (1990b) 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 11:1627-1633. (Pubitemid 20281483)
25. Pozdzik AA, Salmon IJ, Debelle FD, Decaestecker C, Van den Branden C, Verbeelen D, Deschodt-Lanckman MM, Vanherweghem JL, and Nortier JL (2008) Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 73:595-607. (Pubitemid 351264108)
26. Priestap HA (1987) Minor aristolochic acids from Aristolochia argentina and mass spectral analysis of aristolochic acids. Phytochemistry 26:518-529.
27. Rosenquist TA, Einolf HJ, Dickman KG, Wang L, Smith A, and Grollman AP (2010) Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab Dispos 38:761-768.
28. Sato N, Takahashi D, Chen SM, Tsuchiya R, Mukoyama T, Yamagata S, Ogawa M, Yoshida M, Kondo S, Satoh N, et al. (2004) Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol 56:221-229. (Pubitemid 38232752)
29. Schmeiser HH, Janssen JW, Lyons J, Scherf HR, Pfau W, Buchmann A, Bartram CR, and Wiessler M (1990) Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res 50:5464-5469. (Pubitemid 20303005)
30. Schmeiser HH, Schoepe KB, and Wiessler M (1988) DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9:297-303. (Pubitemid 18037995)
31. Shibutani S, Bonala RR, Rosenquist T, Rieger R, Suzuki N, Johnson F, Miller F, and Grollman AP (2010) Detoxification of aristolochic acid I by O-demethylation; less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int J Cancer 127:1021-1027.
32. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, and Grollman AP (2007) Selective toxicity of aristolochic acids I and II. Drug Metab Dispos 35:1217-1222. (Pubitemid 46956445)
33. Simonson GD, Vincent AC, Roberg KJ, Huang Y, and Iwanij V (1994) Molecular cloning and characterization of a novel liver-specific transport protein. J Cell Sci 107:1065-1072.
34. Sweet DH (2005) Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 204:198-215.
35. Taylor S and Harker A (2006) Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal 41:299-303.
36. Ullrich KJ and Rumrich G (1988) Contraluminal transport systems in the proximal renal tubule involved in secretion of organic anions. Am J Physiol Renal Physiol 254:F453-F462.
37. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, and Vanhaelen-Fastre R (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341:387-391. (Pubitemid 23048140)
38. Vanherweghem JL, Tielemans C, Simon J, and Depierreux M (1995) Chinese herbs nephropathy and renal pelvic carcinoma. Nephrol Dial Transplant 10:270-273.
39. VanWert AL, Gionfriddo MR, and Sweet DH (2010) Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos 31:1-71.
40. Vanwert AL, Srimaroeng C, and Sweet DH (2008) Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol 74:122-131. (Pubitemid 351872164)
41. VanWert AL and Sweet DH (2008) Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates. Pharm Res 25:453-462. (Pubitemid 351257979)
42. Weiner IM, Blanchard KC, and Mudge GH (1964) Factors influencing renal excretion of foreign organic acids. Am J Physiol 207:953-963.
43. Xiao Y, Ge M, Xue X, Wang C, Wang H, Wu X, Li L, Liu L, Qi X, Zhang Y, et al. (2008) Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int 73:1231-1239. (Pubitemid 351693146)